Latest Cash Flow News

IPD Group Limited forecasts a modest decline in earnings for FY25, even as revenue grows across key segments and cash flow remains robust.

Yancoal Australia Ltd reported robust 2024 financial results and outlined key corporate governance actions at its 2025 Annual General Meeting, reinforcing its position as a leading coal producer amid market challenges.

Web Travel Group Limited reported a robust 22% increase in Total Transaction Value for FY25, despite a 14% dip in EBITDA due to margin pressures and higher costs. The company is strategically investing in supply and technology to target $10 billion TTV by FY30.

Infratil Limited reported a robust FY2025 with operational EBITDAF nearing NZ$1 billion, driven by strong performances across its core infrastructure sectors and a strategic capital raise to fuel CDC Data Centres’ expansion.

Smartpay has reported an 8.5% rise in consolidated revenue for FY2025, driven by growth in Australia and a bold entry into New Zealand’s acquiring market. However, investments in technology and market expansion have weighed on EBITDA.

Xanadu Mines Limited has received a conditional off-market takeover offer from Bastion Mining Pte Ltd at A$0.08 per share, representing a significant premium. The company’s independent Takeover Committee unanimously recommends acceptance, supported by an independent expert’s fair and reasonable valuation.

Neuren Pharmaceuticals posted record 2024 financials driven by DAYBUE royalties and advanced NNZ-2591 into Phase 3 trials, while launching a $50 million share buy-back amid volatile market sentiment.

Barton Gold Holdings has raised $3 million through a premium-priced placement to fast-track resource upgrade drilling at its Tunkillia Gold Project, boosting its cash reserves to $9 million with minimal dilution.

Antilles Gold’s joint venture has inked key offtake agreements for all gold and copper/gold concentrates from the Nueva Sabana mine, boosting project financing prospects.

Propel Funeral Partners has released its FY25 financial guidance projecting steady revenue growth despite temporary industry volume contraction, alongside announcing the upcoming retirement of its Managing Director and Co-Founder.

ALS Limited delivered a robust FY25 performance with 16% revenue growth to $3 billion and underlying EBIT rising 4.7% to $515 million, driven by strong organic growth and strategic acquisitions. The company is advancing its Nuvisan integration ahead of schedule and has unveiled a $230 million investment plan to expand key laboratories, positioning itself for sustained growth amid market uncertainties.

ALS Limited reported a robust FY25 with $3 billion revenue driven by Life Sciences growth and resilient Commodities, announcing a $350 million equity raise to fund strategic expansion.